TABLE 3.
Reactome pathway analysis (FDR < 10%) using genes that had sex‐DMPs identified within each subgroup from the Pajtler data. No pathways were identified for PF‐EPN‐A, ST‐SE and SP‐MPE.
| Reactome pathway name | FDR |
|---|---|
| PF‐EPN‐B | |
| Mitochondrial biogenesis | 0.09443772 |
| RNA polymerase transcription | 0.09443772 |
| HIV transcription initiation | 0.09443772 |
| RNA polymerase II transcription initiation | 0.09443772 |
| RNA polymerase II HIV promoter escape | 0.09443772 |
| RNA polymerase II promoter escape | 0.09443772 |
| RNA polymerase II transcription initiation and promoter clearance | 0.09443772 |
| Loss of function SMAD4 in cancer | 0.09443772 |
| SMAD4 MH2 domain mutants in cancer | 0.09443772 |
| SMAD2/3 MH2 domain mutants in cancer | 0.09443772 |
| PF‐SE | |
| Signalling by FGFR2 IIIa TM | 0.02478109 |
| FGFR2 mutant receptor activation | 0.02478109 |
| Signalling by FGFR2 in disease | 0.08176046 |
| ST‐EPN‐RELA | |
| Mitochondrial biogenesis | 0.09483678 |
| Keratan sulfate biosynthesis | 0.09483678 |
| ST‐EPN‐YAP1 | |
| GRB7 events in ERBB2 signalling | 0.00282658 |
| Downregulation of ERBB2:ERBB3 signalling | 0.00463631 |
| Constitutive signalling by aberrant PI3K in cancer | 0.00463631 |
| ERBB2 activates PTK6 signalling | 0.00463631 |
| ERBB2 regulates cell motility | 0.00463631 |
| PI3K events in ERBB2 signalling | 0.00516862 |
| PI3K/AKT signalling in cancer | 0.00573294 |
| PI5, PP2A, and IER3 Regulate PI3K/AKT signalling | 0.00573294 |
| Negative regulation of the PI3K.AKT network | 0.00573294 |
| Signalling by ERBB2 TMD/JMD mutants | 0.00573294 |
| Signalling by ERBB2 KD mutants | 0.00639273 |
| SHC1 events in ERBB2 signalling | 0.00639273 |
| Downregulation of ERBB2 signalling | 0.00639273 |
| Signalling ERBB2 in cancer | 0.00639273 |
| Signalling by ERBB2 | 0.01909767 |
| Signalling PTK6 | 0.02077429 |
| Signalling by nonreceptor tyrosine kinases | 0.02077429 |
| Signalling by ERBB4 | 0.02290672 |
| PIP3 activates AKT signalling | 0.03364767 |
| Intracellular signalling by second messengers | 0.04900415 |
| Formyl peptide receptors bind formyl peptides and many other ligands | 0.05411417 |
| Calcitonin‐like ligand receptors | 0.05411417 |
| PI3K events in ERBB4 signalling | 0.07362005 |
| OAS antiviral response | 0.07362005 |
| Interferon alpha/beta signalling | 0.07703115 |
| Diseases of signal transduction by growth factor receptors and second messengers | 0.07703115 |
| SHC1 events in ERBB4 signalling | 0.07703115 |
| GRB2 events in ERBB2 signalling | 0.07703115 |
| TFAP2 (AP‐2) family regulates the transcription of growth factors and their receptors | 0.07703115 |
| Interleukin‐4 and Interleukin‐13 signalling | 0.07867710 |
| Regulation of TP53 activity through methylation | 0.07867710 |
| Intrinsic pathway of fibrin clot formation | 0.07867710 |
| Interferon‐gamma signalling | 0.07867710 |
| PIWI‐interacting RNA (piRNA) biogenesis | 0.07867710 |
| Long‐term potentiation | 0.07867710 |
| ESR‐mediated signalling | 0.07867710 |
| Cytokine signalling in immune system | 0.08308865 |
| DNA damage recognition in GG‐NER | 0.09674191 |